oncology

News in brief: Extended PBS listing for pembrolizumab; 3 oncologists join COSA board; Mandatory vaccination call for all hospital staff

Extended PBS listing for pembrolizumab Pembrolizumab (Keytruda) will be available on the PBS for first-line treatment of patients with unresectable or metastatic mismatch repair deficient (dMMR) colorectal cancer. The decision to expand the list of indications for the checkpoint inhibitor was made at the March 2021 PBAC meeting. “The PBAC considered a revision to the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic